tors. Here, we report that destruxin E (Dx-E), a natural cyclic hexadepsipeptide, reduces A ␤ generation without affecting BACE or PS/ ␥ -secretase activity. In agreement with this, Dx-E did not inhibit Notch signaling. We found that Dx-E decreases colocalization of BACE1 and ␤ APP, which reduces ␤ -cleavage of ␤ APP. Therefore, the data demonstrate that Dx-E represents a novel A ␤ -reducing process which could have fewer side effects than secretase inhibitors.
. In fact, PS1 knockout mice die perinatally and show the Notch phenotype due to attenuation of NICD (Notch intracellular cytoplasmic domain) generation from Notch receptors [6, 7] . BACE1 knockout mice also show the peripheral nerve hypomyelination phenotype caused by ablation of neuregulin 1 cleavage [5] . It is unclear whether targeting secretases is necessary for inhibiting A ␤ generation.
Here, we performed high-throughput screening for inhibitors of A ␤ generation and identified destruxin E (Dx-E), a natural compound derived from an entomopathogenic fungus. Interestingly, Dx-E reduced ␤ -cleavage of ␤ -amyloid protein precursor ( ␤ APP) but did not inhibit the secretases. The existence of such a compound suggests that there is a novel mechanism for inhibiting A ␤ generation.
Materials and Methods

Antibodies and Reagents
Anti-A ␤ antibodies 6E10 and 4G8 were from Signet Laboratories (Dedham, Mass., USA). The anti-sAPP ␤ Swedish (sw) antibody was from IBL (Takasaki, Japan). The anti-BACE1 antibody was from Chemicon (Temecula, Calif., USA). The anti-Na + -K + -ATPase was from Upstate Biotechnology. The anti-calnexin antibody was from Stressgen. The anti-early-endosome-antigen (EEA) and anti-GM130 antibodies were from BD Transduction Laboratories. The ␥ -secretase inhibitors DAPT and L-685,458 and the BACE inhibitor N-(1S,2R)-1-benzyl-3-(cyclopropylamino)-2-hydroxypropyl-5-[methyl(methylsulfonyl)amino-N -(1R)-1-phenylethyl]isophthalamide (inhibitor IV) were purchased from Calbiochem (San Diego, Calif., USA). The ␥ -secretase substrate NMA-GGVVIATVK(DNP)-DRDRDR-NH 2 was purchased from Calbiochem, and the ␤ -secretase substrate MOCAc-SEVNLDAEFRK(Dnp)-RR-NH 2 was from Peptide Institute (Osaka, Japan). Dx-E was purified by Shionogi and Co. Ltd. In the measurement of A ␤ 40 and A ␤ 42 at a 384-well plate format, the addition of compounds and seeding of ␤ APP-overexpressing cells were simultaneously performed and incubated for 24 h. In other experiments, compounds were mixed in culture medium and layered onto adherent cells.
Cell Culture K293 and SH-SY5Y cells stably expressing ␤ APP/PS1/Notch derivatives were maintained in DMEM containing 10% FCS and antibiotics (200 g/ml G418 for ␤ APP selection, 200 g/ml zeocin for PS1 selection and 100 g/ml hygromycin for Notch1 selection).
Measurement of A ␤ Secretion
For high-throughput screening, A ␤ 40 secretion was measured with a homogeneous time-resolved fluorescence kit (Nihon Schering, Osaka, Japan) as described in the manufacturer's instructions. Briefly, in a typical 384-well plate assay, 55 ng/ml antibody europium cryptate, 400 ng/ml antibody XL665 and 50 m M phosphate buffer (pH 7.4) containing 0.2% BSA and 0.5 M FK were added into each well. Samples of conditioned cell culture medium or synthetic peptide standards were added to give a total assay volume of 20 l/well. The reaction mixture was left at 4 ° C to allow equilibrium binding and then read on an ALVO multilabel counter (Wallac Oy and Perkin Elmer Inc., Turku, Finland). For measurement of A ␤ 40 and A ␤ 42 in a 96-well plate format, an A ␤ sandwich enzyme-linked immunosorbent assay (Wako, Japan) was used. The cells were incubated for 16 h with compounds. A ␤ levels were normalized by cell viability as measured using a WST system (Nacalai Tesque, Japan).
Pulse-Chase Experiments
Pulse-chase experiments were carried out as previously described [8] .
Notch Downstream Assays
Notch signal reporter assays were carried out as previously described [9] .
In vitro ␤ -Secretase Assay
The peptide substrate for ␤ -secretase (biotin-X-SEVNLDAE-FRHDSGC) was labeled with europium cryptate (CIS Bio, Marcoule, France). Recombinant ectodomain human BACE1 (R & D Systems) in reaction buffer (50 m M sodium acetate, pH 5.0, and 0.008% Triton X-100) with various concentrations of inhibitors were mixed with the substrate (18 n M ) in 96-well plates and then incubated for 3 h at 30 ° C. Streptavidin-XL665 (0.4 g/well) was added, and the reaction was incubated for 1 h at 30 ° C. The homogeneous time-resolved fluorescence value [(ratio of fluorescence at 665 nm to that at 620 nm) ! 10,000] in each well was measured using an ALVO multilabel counter.
In vitro ␥ -Secretase Assay
Cell-free in vitro ␥ -secretase assays were carried out as previously described [10, 11] .
Cell-Free ␤ -Secretase Assay
Following starvation in methionine-and serum-free minimal essential medium for 40 min, the K293 cells stably expressing sw ␤ APP were metabolically labeled with 450 Ci of [ 35 S]methionine/cysteine (Redivue Promix; Amersham) for 20 min in methionine-and serum-free minimal essential medium. The crude membrane fraction was extracted, and the cell-free assay was performed as previously described with a minor change [12] . Briefly, samples of the crude membrane fraction were preincubated with each compound for 1 h and then incubated for 40 min at 37 ° C (cell-free incubation). The reaction was solubilized by the addition of 10 ! radioimmunoprecipitation assay buffer (1% sodium dodecyl sulfate, 5% deoxycholate, 10% Triton-X 100) and diluted with phosphate-buffered saline containing protease inhibitor cocktail. The ␤ APP C-terminal fragments (CTF) produced during the cell-free reaction were immunoprecipitated with antiserum 6618 [12] . Immunoprecipitates were separated on 10-20% Tris-tricine gels (Invitrogen, Carlsbad, Calif., USA) and analyzed by autoradiography.
Immunocytochemistry K293 cells stably expressing sw ␤ APP and wild-type (wt) PS1 were cultured on poly-L -lysine-coated coverslips. Cells were treated with the reagents at indicated concentrations for 16 h. Cells were fixed in 4% paraformaldehyde, permeabilized by 0.1% Triton-X 100 and blocked with 1% defatted milk, in phosphate-buffered saline. The following primary antibodies were used for immunostaining: Monoclonal antibodies for BACE1 and ␤ APP (22C11) were from Chemicon. Polyclonal antibody for N-terminal (46-65) BACE1 was from Calbiochem. Polyclonal antibody 6618 was raised against the C terminus of ␤ APP [12] . Secondary antibodies used were labeled with Alexa 488 or 594 (Invitrogen).
Subcellular Fractionation
Subcellular fractionation was carried out as previously described [12] .
Results
Dx-E Inhibits A ␤ Generation
A search for inhibitors of A ␤ generation in a library of more than approximately 50,000 compounds by highthroughput screening identified Dx-E, a cyclodepepsipeptide ( fig. 1 A) . To confirm the ability of Dx-E to inhibit A ␤ generation, we labeled SH-SY5Y cells stably expressing wt ␤ APP by a 30-min pulse with [
35 S]methionine followed by a 2-hour chase. As shown in figure 1 B, Dx-E (1 M ) decreased the level of secreted A ␤ /p3 species (IC 50 approx. 230 n M ; fig. 1 B, upper panel), although it did not significantly change the rate of ␤ APP holoprotein degradation ( fig. 1 B, middle and lower panels). We also examined whether Dx-E affects the rate of A ␤ degradation in cell culture. Cells were incubated in conditioned medium containing radiolabeled A ␤ and in the absence or presence of Dx-E. As shown in figure 1 C, the rate of A ␤ degradation was unchanged by Dx-E treatment. Thus, it appears that Dx-E inhibits A ␤ /p3 generation in cell culture.
Dx-E Does Not Affect ␥ -Secretase Cleavage of ␤ APP
A ␤ generation requires two independent proteolytic steps, namely ␤ -and ␥ -cleavages. We first evaluated the possibility that Dx-E reduces ␥ -secretase activity. We performed an in vitro ␥ -secretase assay [10] using an intramolecularly quenched fluorogenic peptide probe, NMA-GGVVIATVK(DNP)-DRDRDR-NH 2 . This probe was mixed with the 1% CHAPSO-soluble membrane fraction of cultured cells (containing active PS/ ␥ -secretase complex) and incubated for 16 h with Dx-E or L685,458, a specific ␥ -secretase inhibitor. As shown in figure 2 A, Dx-E (0.003-10 M ) did not affect ␥ -secretase activity in vitro, although L-685,458 inhibited the activity in a dose-dependent manner. Next, we analyzed whether Dx-E inhibits ␥ -cleavage of ␤ APP in living cells ( fig. 2 B) . For the experiments, we used K293 cells stably expressing the CTF of ␤ APP (CTF100), a constitutive substrate for PS/ ␥ -secretase. In contrast to the case of full-length ␤ APP, Dx-E did not inhibit A ␤ generation from CTF100 ( fig. 2 B) . Collectively, these results show that the reduction of A ␤ generation by Dx-E is not due to inhibition of ␥ -secretase/cleavage.
Modulators of ␥ -secretase, such as a subset of nonsteroidal anti-inflammatory drugs, can inhibit A ␤ generation at relatively higher concentrations than those causing changes in the relative ratio of A ␤ 42 generation [13] . We therefore investigated whether Dx-E is a ␥ -secretase modulator. Pulse-chase experiments revealed that Dx-E does not change the relative ratio of A ␤ 42 species at lower concentrations, indicating that it is not a ␥ -secretase modulator.
Dx-E Does Not Affect Notch1 Degradation or Notch Signaling
The major side effects of ␥ -secretase-inhibiting compounds are due to inhibition of Notch signaling. If Dx-E does not affect the activity of PS/ ␥ -secretase, it should have no influence on Notch signaling. To confirm this, we examined whether Dx-E affects Notch signaling in cell culture ( fig. 3 A) . We used cells stably expressing the N1CS construct, a derivative of the Notch1 receptor [14] . The N1CS polypeptide constitutively undergoes sequential endoproteolysis in the absence of ligand binding [14] . The extent of Notch signaling was determined using a luciferase reporter assay in cells expressing HES-Y [9] . As shown in figure 3 A, Dx-E treatment did not affect the rate of Notch signal transmission, although it dose-dependently reduced A ␤ production. Also, as expected, DAPT, a specific ␥ -secretase inhibitor, reduced both A ␤ generation and Notch signaling ( fig. 3 B) . Therefore, Dx-E does not perturb Notch signaling even though it inhibits A ␤ / p3 generation.
The sequential endoproteolysis of Notch1 consists of S2/S3/S4 cleavages. NICD is generated by the S3 cleavage. Because Dx-E has distinct effects on the generation of 〈 ␤ and NICD, we examined whether its effects are substrate specific. Thus, we analyzed secretion of S2/S4 cleavagederived N ␤ , also known as Notch1 A ␤ -like peptides [8, 15] ( fig. 3 C) . In contrast to specific ␥ -secretase inhibitors, Dx-E treatment did not inhibit N ␤ secretion from N1CS-expressing cells ( fig. 3 C) . Therefore, it appears that Dx-E inhibits sequential endoproteolysis of ␤ APP but not of Notch1.
Dx-E Does Not Affect ␤ -Cleavage of ␤ APP in vitro
Dx-E reduces A ␤ generation without affecting ␥ -cleavage of ␤ APP or Notch signaling/cleavage. Therefore, we examined whether Dx-E affects ␤ -cleavage of ␤ APP by BACE. We examined ␤ -secretase activity in vitro using an intramolecularly quenched fluorogenic peptide probe, MOCAc-SEVNLDAEFRK(Dnp)-RR-NH 2 , and recombinant BACE1. Dx-E did not affect BACE1 activity at any concentration of Dx-E tested (0.6 n M to 10 M ), although the specific BACE inhibitor, inhibitor IV (IC 50 approx. 20 n M ), affected the activity ( fig. 4 A) . We also used a newly established cell-free ␤ -secretase assay that can detect de novo generation of CTF ␤ from ␤ APP holoprotein ( fig. 4 B) . After a 20-min pulse with [
35 S]methionine, we extracted the crude membrane fraction from cultured cells and incubated it for 40 min in vitro. Notably, addition of Dx-E to the membrane fraction did not decrease the generation of CTF ␤ , although inhibitor IV decreased the level of CTF ␤ by approximately 70% (p ! 0.001 (t test); fig. 4 B, lower panel) . These results indicate that Dx-E does not affect BACE activity. 
Dx-E Inhibits ␤ -Cleavage of ␤ APP in Living Cells
We further examined whether Dx-E affects ␤ -cleavage by BACE in living cells. K293 ( fig. 4 C) and SH-SY5Y ( fig. 4 D) cells expressing ␤ APP were pulse labeled for 10 min and chased for the indicated time. Strikingly, in both cell lines, Dx-E drastically decreased secretion of soluble ␤ APP ␤ , which is released by ␤ -cleavage of ␤ APP, at the same concentration that reduced A ␤ generation ( fig. 4 C, first panel, and fig. 4 D, upper panel) . In addition, Dx-E slightly enhanced the secretion of soluble ␤ APP ␣ , which is probably a secondary effect due to decreased ␤ -cleavage of ␤ APP ( fig. 4 D, lower panel) . Dx 
Dx-E Decreases Colocalization of ␤ APP and BACE1 in Cultured Cells
Our data that Dx-E decreases ␤ -cleavage of ␤ APP in living cells without targeting to BACE enzyme prompted us to study a possibility that it affects relative subcellular locations of BACE and ␤ APP. To address this, we performed immunohistochemical analysis ( fig. 5 A-J) . In untreated cultured cells, immunostaining with anti-␤ APP extracellular domain antibody (22C11, red) and BACE1 N-terminal domain antibody (Calbiochem 195101, green) yielded substantial amounts of yellow colors which implies colocalization of the enzyme and the substrate ( fig. 5 A, B) . However, upon Dx-E treatment, a portion of the yellow staining drastically decreased, while red/green stainings reciprocally increased ( fig. 5 C, D) , indicating a marked decrease in the colocalization. In addition, we compared the distribution of each green or red staining with or without Dx-E treatment ( fig. 5 E-G, H-J), and found that the change of BACE1 distribution looked greater than that of ␤ APP.
To further confirm that Dx-E decreases the colocalization of ␤ APP and BACE1, we performed subcellular fractionation of cultured cells and observed the colocalization in each organelle. We immunoblotted each fraction with antibodies to the Na + -K + -ATPase ␣ 1 -subunit (for plasma membrane marker), EEA1 (for endosome marker), calnexin (for endoplasmic reticulum marker) and GM130 (for Golgi marker), which confirmed successful separation of each organelle ( fig. 6 A, B) . Continuously, we tried to observe changes in subcellular distribution of ␤ APP/BACE1 with or without the treatment of Dx-E ( fig. 6 C) . Strikingly, the major distribution of BACE1 moved from the relatively light fractions (approx. fractions 4-7) to heavier fractions (approx. fractions 7-9; fig. 6 C, first and second panels). However, distribution of ␤ APP holoprotein and those of the organelle marker proteins did not change so much ( fig. 6 C, third to fourth panels, and fig. 6 A, B) . Both the biochemical and immunohistochemical data indicate that Dx-E induces drastic changes in the subcellular locations of BACE1. Collectively, we suggest that Dx-E induces decreased colocalization of matured ␤ APP holoprotein and BACE1 enzyme, which may reduce ␤ -cleavage.
Discussion
In this study, we demonstrated that Dx-E reduces A ␤ generation in a secretase-independent manner. Dx-E inhibits ␤ -cleavage of ␤ APP, but it does not affect ␤ -and ␥ -secretases. Curiously, colocalization of BACE1 and ␤ APP was reduced by Dx-E. Our results suggest that Dx-E represents a novel and advantageous means of reducing A ␤ production in Alzheimer disease.
Dx-E, a member of the destruxin family, is a cyclic hexadepsipeptide containing an ␣ -hydroxy acid and 5 amino acid residues [16] . This peptide is reported to have several biological activities, including inhibition of vacuolar-type H + -ATPase, cell cycle arrest and inhibition of bone resorption [16] . The ability of Dx-E to reduce A ␤ production might be related to these effects. In addition, Dx-E is not the only member of the destruxin family that can inhibit A ␤ production; we found that destruxin C is a weak inhibitor of A ␤ production [Itoh N., unpubl. observations]. Like Dx-E, bafilomycin and concanamycin inhibit the vacuolar-type H + -ATPase and reduce A ␤ secretion from sw-␤ APP-expressing cells [17, 18] . However, their mechanism of inhibiting ␤ -cleavage is not well understood.
To reduce A ␤ generation, inhibitors of either ␤ -cleavage or ␥ -cleavage of ␤ APP have been developed. Since typical BACE or PS/ ␥ -secretase inhibitors inhibit the enzymatic activities, they inevitably perturb cleavages of substrates other than ␤ APP. Inhibiting the enzymatic activities may cause unfavorable side effects because these enzymes are deeply involved in neuregulin/Notch signaling and play important roles in vivo. Thus, atypical compounds have been of note which inhibit A ␤ generation without disturbing cleavages of other substrates. Especially, inhibitors that do not affect Notch signaling have been sought. For example, Gleevec is thought to target the PS/ ␥ -secretase because it inhibits the de novo generation of A ␤ in a cell-free assay [19] . How other compounds such as JLK (nonpeptidic inhibitors of ␥ -secretase), glycogen synthase kinase 3 ␣ inhibitors, cerebrolysin and berberine inhibit A ␤ generation is unclear [20] [21] [22] .
Dx-E, which is neither a BACE nor PS/ ␥ -secretase inhibitor, can reduce A ␤ generation. Dx-E may decrease A ␤ by reducing colocalization of ␤ APP and BACE1. The reduction of the colocalization is probably induced by drastic changes in the subcellular locations of BACE1. Since Dx-E does not change subcellular locations of other proteins such as ␤ APP, Na + -K + -ATPase ␣ 1 -subunit, EEA1, calnexin and GM130, the effect of Dx-E may be specific to BACE1. Dx-E may specifically affect trafficking of BACE1. Further study will be needed to elucidate how it is achieved. In future, we expect research and development of small-molecule inhibitors with processes similar to Dx-E.
